Ari-0001
Hematopoietic/Lymphoid Cancer
First Affiliated Hospital of Wenzhou Medical UniversityCell therapyPhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Hematopoietic/Lymphoid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BBB |
Zofran Yale University | Phase 3 | BB |
Fludarabine National Cancer Institute (NCI) | Phase 2 | BB |
Granisetron Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Palonosetron Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 26 →
Same molecule, other indications
Ari-0001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →